# DX-8951f in Treating Children With Advanced Solid Tumors or Lymphomas

> **NCT00004212** · PHASE1 · COMPLETED · sponsor: **Daiichi Sankyo**

## Conditions studied

- Brain and Central Nervous System Tumors
- Lymphoma
- Unspecified Childhood Solid Tumor, Protocol Specific

## Interventions

- **BIOLOGICAL:** filgrastim
- **DRUG:** exatecan mesylate

## Key facts

- **NCT ID:** NCT00004212
- **Lead sponsor:** Daiichi Sankyo
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1999-09
- **Primary completion:** 2004-04
- **Final completion:** 2004-04
- **Target enrollment:** — (—)
- **Last updated:** 2012-05-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00004212

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00004212, "DX-8951f in Treating Children With Advanced Solid Tumors or Lymphomas". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT00004212. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*